INTRODUCTION: Oral antidiabetes medications, including @entity5735 inhibitors ( @entity5735 is) @entity15072 and @entity12350 , are used for the treatment of @entity2175 ( @entity2175 ). The study objective was to compare all-cause and @entity6 following initiation of @entity15072 or @entity12350 . METHODS: @entity1 aged >= 18  years initiating @entity15072 or @entity12350 between January 1, 2009 and January 31, 2012 in the Truven Health MarketScan Commercial and Medicare Supplemental databases were identified. @entity1 were required to have continuous enrollment for >= 365  days before and >= 365  days after the index date (date of the first @entity15072 or @entity12350 claim). Additionally, @entity1 were required to have a claim with a @entity2175 diagnosis (ICD-9-CM 250.*0, 250.*2) and no claims for a @entity5735 i medication before the index date. All-cause and @entity6 -related medical costs and total costs (including pharmacy costs) were captured over the 1-year follow-up period. Generalized linear models with log link and gamma distribution were fit to compare costs between the two cohorts using cost ratios, controlling for @entity1 baseline characteristics. Recycled prediction methods were used to generate adjusted predicted costs and confidence intervals. RESULTS: The final sample comprised 3354 @entity15072 initiators and 26,895 @entity12350 initiators. The average age of @entity15072 and @entity12350 initiators was 57  years and just over 50% were males. After adjusting for baseline characteristics, @entity15072 @entity1 had significantly lower average all-cause medical costs (cost ratio  =  0.901, P  <  0.001; predicted mean costs:  8687 vs.  9646) compared with @entity12350 @entity1 over the 1-year follow-up. Findings were consistent for @entity6 -related medical costs (cost ratio  =  0.890, P  <  0.001; predicted mean costs:  2180 vs.  2450). Total costs were also lower for @entity15072 initiators (cost ratio  =  0.950, P  =  0.002; predicted mean costs:  13,911 vs.  14,651) over the 1-year follow-up period. CONCLUSION: Initiation of treatment with @entity15072 was associated with lower medical costs over 1  year compared with initiation of @entity12350 among adults with @entity2175 . FUNDING: AstraZeneca.

Healthcare Costs Among Adults with @entity2175 XXXX Inhibitors.

@entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes', 'T2D'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity5735 :: ('1803', 'Gene') :: ['dipeptidyl peptidase-4', 'DPP-4'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes-related costs', 'diabetes'] @entity15072 :: ('MESH:C502994', 'Chemical') :: ['saxagliptin'] @entity12350 :: ('MESH:C496398', 'Chemical') :: ['sitagliptin']
@entity5735 :: (1803,Gene) :: ['DPP-4']
